Events

Retiro De Equipo (Recall) de PARADIGM QUICK-SET INFUSION SETS

Según Health Canada (via FOI), este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en Canada que fue producido por MEDTRONIC OF CANADA LTD..

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
    Recall
  • ID del evento
    18735
  • Clase de Riesgo del Evento
    I
  • Fecha de inicio del evento
    2013-06-13
  • País del evento
    Canada
  • Fuente del evento
    HC
  • Notas / Alertas
    Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
  • Notas adicionales en la data
  • Causa
    Medtronic has become aware of a potential safety issue that can occur if insulin or other fluids come in contact with the inside of the connector on medtronic paradigm infusion sets. this recall also provides information on how to prevent this from occurring. exposure of the inside of the tubing connector to fluid is most likely to occur if insulin is spilled on the top of the insulin reservoir when the reservoir is removed from the transfer guard after filling the reservoir from a vial of insulin. if this occurs the insulin can temporarily block the vents in the connector that allow the pump to properly prime. if these vents are blocked this can potentially result in too much or too little insulin being delivered which may cause hypoglycemia or hyperglycemia which in extreme cases may cause loss of consciousness or death.

Device

PARADIGM QUICK-SET INFUSION SETS
  • Modelo / Serial
    Model Catalog: MMT-396600 (Lot serial: All lots contact manf); Model Catalog: MMT-386600 (Lot serial: All lots contact manf); Model Catalog: MMT-387600 (Lot serial: All lots contact manf); Model Catalog: MMT-394600 (Lot serial: All lots contact manf); Model Catalog: MMT-397600 (Lot serial: All lots contact manf); Model Catalog: MMT-398600 (Lot serial: All lots contact manf); Model Catalog: MMT-399600 (Lot serial: All lots contact manf); Model Catalog: MMT-874 (Lot serial: All lots contact manf); Model Catalog: MMT-864 (Lot serial: All lots contact manf); Model Catalog: MMT-862 (Lot serial: All lots contact manf); Model Catalog: MMT-840 (Lot serial: All lots contact manf); Model Catalog: MMT-379 (Lot serial: All lots contact manf); Model Catalog: MMT-380 (Lot serial: All lots contact manf); Model Catalog: MMT-377600 (Lot serial: All lots contact manf); Model Catalog: MMT-384600 (Lot serial: All lots contact manf); Model Catalog: MMT-378600 (Lot serial: All lots contact manf); Model Catalog: MMT-368600 (Lot se
  • Clasificación del producto
    General Hospital and Personal Use Devices
  • Descripción del producto
    PARADIGM QUICK-SET INFUSION SETS
  • Manufacturer
    MEDTRONIC OF CANADA LTD.

Manufacturer

MEDTRONIC OF CANADA LTD.
  • Dirección del fabricante
    BRAMPTON
  • Empresa matriz del fabricante (2017)
    Medtronic plc
  • Comentario del fabricante
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    HC